CN108685981A - A kind of notoginseng-red sage capsule and preparation method thereof - Google Patents
A kind of notoginseng-red sage capsule and preparation method thereof Download PDFInfo
- Publication number
- CN108685981A CN108685981A CN201810802196.4A CN201810802196A CN108685981A CN 108685981 A CN108685981 A CN 108685981A CN 201810802196 A CN201810802196 A CN 201810802196A CN 108685981 A CN108685981 A CN 108685981A
- Authority
- CN
- China
- Prior art keywords
- notoginseng
- capsule
- red sage
- parts
- content
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Dermatology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Medicines Containing Plant Substances (AREA)
- Anesthesiology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Toxicology (AREA)
Abstract
The invention discloses a kind of notoginseng-red sage capsules, including content and capsule shells, by weight, the content includes 0.5~2.5 part of 150~300 parts of Radix Notoginseng powder, 150~250 parts of Salvia root P.E, 10~50 parts of yeast beta-dextran, silica 1~10 part and magnesium stearate.The invention also discloses a kind of preparation methods of notoginseng-red sage capsule.Notoginseng-red sage capsule of the present invention can significantly reduce the wheal quantity on chronic urticaria patients body and reduce itch degree, it is not recurred substantially after curing chronic urticaria, simultaneously, compared to loratadine tablet, the notoginseng-red sage capsule there is also Small side effects, patient sleeps' situation and fatiguability situation and other effects can be improved.
Description
Technical field
The present invention relates to functional health-care food and field of pharmaceutical technology more particularly to a kind of notoginseng-red sage capsule and its systems
Preparation Method.
Background technology
Radix Notoginseng, alias pseudo-ginseng, radix notoginseng, rhizome of Scopulosus Bergenia, invaluable and blood ginseng, class cone or cylindrical.Its surface ash
Brown or lark have interrupted vertical wrinkle and supporting root trace.There is stem trace on top, around there is strumae.Weight, matter is solid, hits
Po Hou skin zones often detach with woody part, section celadon, yellow green or canescence, and there is fine brown spot in skin zone, and micro- woody part is in put
Penetrate shape texture.Gas is micro-, bitter and sweetish after-taste.Animal experiment shows that ginsenoside Rg's class Central nervous has an excitation, and Rb
Class then has inhibiting effect, arasaponin to can inhibit platelet aggregation, and Notogineng Extract has cardiac stimulant, decompression, liver protection, anti-inflammatory, drop
Low blood cholesterol, immunological regulation and antivirus action have hemostasis, platelet aggregation-against and molten to blood and hemopoietic system
The effects that bolt, haemolysis, hematopoiesis;To cardiovascular system have anti-arrhythmia, antiatherosclerosis, resist oxygen lack and Hemorrhagic shock,
The effects that improving cerebral ischemia;Have the effects that nervous centralis inhibition, analgesia to nervous system;Improving immunocompetence protects liver
Function, it is antitumor, it slows down aging, hypoglycemic, anti-inflammatory, Auto-regulator metabolism promotes growth;Toxicity is relatively low, and long-term administration is basic
Without side reaction.
Radix Salviae Miltiorrhizae rhizome is short and thick, surface brownish red or dark brownish red, coarse, has vertical wrinkle.Old root crust is loose, more aobvious purple palm fibres
Color, normal flake off.Matter is hard and crisp, and section is loose, there is crack or slightly smooth and fine and close, skin zone's brownish red, woody part sallow
Color or puce, vessel cluster yellow-white, are arranged radially.Gas is micro-, and mildly bitter flavor is puckery.Red sage formulation can make the experimental animal heart coronal
Asrteriectasia makes heart function be obviously improved, and injection has blood coagulation resisting function, extract to have bacteriostasis, hidden Radix Salviae Miltiorrhizae in vitro
Ketone is the active ingredient of antibacterial.Salvia root P.E protects cardiac-cerebral vascular, reducing blood lipid, antiatherosclerosis, promoting blood circulation and removing blood stasis, enhancing
Hypoxia-bearing capability, enhancing immune function, anti-inflammatory and antiallergy, protect liver, anti-gastric-ulcer, antitumor, sedation and analgesia, to respiratory system
There is protective effect, improves renal function, anti-oxidant, antibacterial, promote skin wound, union, have gonadotropic Effect.
Nettle rash is otherwise known as " wheal " or " wheal ", is disease extremely common in Dermatology Outpatient Department, incidence
It is high.Nettle rash is a kind of autoimmune disease for the allergy that immune system occurs, and is mainly shown as with skin, sticks
A kind of localized edema reaction that film thin vessels are expanded and permeability increases and are occurred.Its major clinical feature is fash, oedema
The wheal that property erythema, size and form differ, while with different degrees of pruritis.Nettle rash is divided into according to the recovery from illness time limit
Chronic urticaria (CU) and acute urticaria (AU), wherein symptom at least two occurs on a daily or weekly basis for chronic urticaria patients
It is secondary, often six weeks or more seizure of disease period, and its pathogenesis is extremely complex, the cause of disease is difficult to determine.Currently, clinically to slow
Property nettle rash therapeutic modality have antihistamine drug, glucocorticoid, immunosuppressor and non-specific antiallergy etc., such as often
H1 receptor antagonist pharmaceuticals-loratadine tablet for treating chronic urticaria, but there are disease specific aims for this kind of drug
It is not strong, therapeutic effect is not satisfactory, be discontinued after easy drawbacks such as recurrence, meanwhile, take such treatment chronic urticaria drug for a long time
It can also cause adverse reactions, the severe patients such as tired, sleep difference that can also influence the liver kidney and endocrine metabolic diseases function of patient, it is difficult to full
Long-term treatment demand of the foot to chronic urticaria.
Invention content
For overcome the deficiencies in the prior art, one of the objects of the present invention is to provide a kind of notoginseng-red sage capsule, with gram
Specific aim that clothes are currently used for the drug generally existing for the treatment of chronic urticaria is not strong, therapeutic effect is not satisfactory, be discontinued after easily
The drawbacks such as side effect is apparent are taken in recurrence for a long time.
The second object of the present invention is to provide a kind of preparation method of notoginseng-red sage capsule, is prepared by this method
A kind of notoginseng-red sage capsule, to overcome, the specific aim for the drug generally existing for being currently used for treatment chronic urticaria is not strong, treats
Effect is not satisfactory, be discontinued after easily recur, take the drawbacks such as side effect is apparent for a long time.
An object of the present invention adopts the following technical scheme that realization:
A kind of notoginseng-red sage capsule, including content and capsule shells, by weight, the content includes Radix Notoginseng powder
150~300 parts, 150~250 parts of Salvia root P.E, 10~50 parts of yeast beta-dextran, silica 1~10 part and tristearin
0.5~2.5 part of sour magnesium.
Further, the Radix Notoginseng powder is 200~250 parts, and the Salvia root P.E is 170~210 parts, the yeast β-
Glucan is 25~40 parts, and the silica is 2~5 parts, and the magnesium stearate is 1~2 part.
Further, the Radix Notoginseng powder is 225 parts, and the Salvia root P.E is 186.67 parts, the yeast beta-dextran
It it is 33.33 parts, the silica is 3.6 parts, and the magnesium stearate is 1.4 parts.
Further, the fineness of the Radix Notoginseng powder is higher than 100 mesh, and the Radix Notoginseng powder is used to prepare three after radiation sterilizing
Seven capsule of red sage root.
Further, the ethyl alcohol that the Salvia root P.E is 50~75% extracts concentrate made from Radix Salviae Miltiorrhizae.
The second object of the present invention adopts the following technical scheme that realization:
A kind of preparation method of notoginseng-red sage capsule, includes the following steps:
Prepare content:Radix Notoginseng powder, Salvia root P.E, yeast beta-dextran, silica and hard are weighed according to proportioning
Fatty acid magnesium is uniformly mixed and crosses 80 mesh sieve;
Compression moulding:Capsule shells feed liquid and content material liquid compression moulding are taken, 0.45g/ notoginseng-red sage capsules are made.
Further, further include probiotics fermention step, purified water dilution is added into content obtained, it will be diluted
Content is transferred to curing at 105~121 DEG C, 5~15min of sterilizing, and cooled to room temperature is inoculated with 1~10 part of probiotics,
Hypoxemia ferments 5~10 days under the conditions of 35~40 DEG C, and after fermentation, concentrated broth is for use for hypoxemia;
Wherein, the weight ratio of content feed liquid and purified water is 1:1~5, at interval of 6~12h in hypoxemia fermentation process
Stirring content feed liquid is primary, and the oxyty in the hypoxemia fermentation is 6~10%;
And the probiotics are at least one of Lactobacillus rhamnosus and lactobacillus plantarum and Bulgarian bar
The mix bacterium agent that bacterium, bifidobacterium longum and aspergillus oryzae form.
Further, the probiotics are Lactobacillus rhamnosus, lactobacillus plantarum, bacillus bulgaricus, long bifid bar
The mix bacterium agent of bacterium and aspergillus oryzae composition, the probiotics are 3~10 parts;
Wherein, the quantity of Lactobacillus rhamnosus, lactobacillus plantarum, bacillus bulgaricus, bifidobacterium longum and aspergillus oryzae
The ratio between be 1:1~5:1:1~5:10.
Further, hypoxemia ferments 7 days under the conditions of the probiotics are 4.5 parts, 38 DEG C;
The zymotic fluid is concentrated into water content and is less than 25%.
Further, in the probiotics, the quantity of Lactobacillus rhamnosus is 1 × 106It is a, the quantity of lactobacillus plantarum
It is 4 × 106A, the quantity of bacillus bulgaricus is 1 × 106A, the quantity of bifidobacterium longum is 4 × 106It is a, the number of aspergillus oryzae
Amount is 8 × 106It is a.
Compared with prior art, the beneficial effects of the present invention are:
(1) notoginseng-red sage capsule of the present invention can significantly reduce the wheal quantity on chronic urticaria patients body and reduce
Itch degree.Compared to loratadine tablet, notoginseng-red sage capsule of the present invention does not occur chronic substantially after curing chronic urticaria
The case where nettle rash recurs.Meanwhile compared to loratadine tablet, the notoginseng-red sage capsule there is also Small side effects, can improve
Immunity of organism is horizontal, improves patient sleeps' situation and fatiguability situation and other effects.
(2) the notoginseng-red sage capsule that the preparation method of notoginseng-red sage capsule of the present invention is prepared, can be effectively retained Radix Notoginseng
The active constituent of powder, Radix Salviae Miltiorrhizae passes through matching for Radix Notoginseng powder, Salvia root P.E, yeast beta-dextran, silica and magnesium stearate
5 effects are played the role of curing chronic urticaria.
Specific implementation mode
In the following, in conjunction with specific implementation mode, the present invention is described further, it should be noted that is do not collided
Under the premise of, new embodiment can be formed between various embodiments described below or between each technical characteristic in any combination.
Hereinafter, illustrating the preparation process of notoginseng-red sage capsule of the present invention by embodiment 1~12.
Embodiment 1-6 is 6 kinds of different notoginseng-red sage capsules, and the preparation process of this 6 kinds different notoginseng-red sage capsules is equal
Including preparing Salvia root P.E, preparing content step and compression moulding step.The preparation of this 6 kinds different notoginseng-red sage capsules
The difference of process is only that raw material proportioning difference.
Prepare Salvia root P.E:It takes Radix Salviae Miltiorrhizae through medicinal material cutting machine segment to 0.5~1cm, the Radix Salviae Miltiorrhizae of segment is placed in extraction
In tank, it is added 5 times of ethanol water, circumfluence distillation 2.5h continues at 80 DEG C, concentrates under the conditions of -0.05~-0.08MPa
The Radix Salviae Miltiorrhizae extractum for being 1.3~1.4 at proportion, i.e. Salvia root P.E.
Prepare content:Radix Notoginseng powder, Salvia root P.E, yeast beta-dextran, silica and hard are weighed according to proportioning
Fatty acid magnesium is uniformly mixed and crosses 80 mesh sieve.Wherein, the fineness of Radix Notoginseng powder is higher than 100 mesh (i.e. granularity is less than 150 μm), Radix Notoginseng powder
It is used to prepare content after ultraviolet irradiation is sterilized.
Compression moulding:Capsule shells feed liquid and content material liquid compression moulding are taken, 0.45g/ notoginseng-red sage capsules are made.
Table 1
| Radix Notoginseng powder (g) | Salvia root P.E (g) | Yeast beta-dextran (g) | Silica (g) | Magnesium stearate (g) | |
| Embodiment 1 | 150 | 250 | 10 | 1 | 2.5 |
| Embodiment 2 | 200 | 210 | 40 | 2 | 2 |
| Embodiment 3 | 225 | 186.67 | 33.33 | 3.6 | 1.4 |
| Embodiment 4 | 250 | 170 | 25 | 5 | 1.2 |
| Embodiment 5 | 270 | 230 | 20 | 8 | 1 |
| Embodiment 6 | 300 | 150 | 50 | 10 | 0.5 |
Embodiment 7-12 is other 6 kinds different notoginseng-red sage capsules, the preparation of this 6 kinds different notoginseng-red sage capsules
Cheng Jun includes preparing content step, probiotics fermention step and compression moulding step.The difference of embodiment 7 and embodiment 3 is only
It is to include probiotics fermention step;Embodiment 8 is differed only in embodiment 3 comprising probiotics fermention step;Embodiment 9
With differing only in comprising probiotics fermention step for embodiment 3;Embodiment 10 is differed only in embodiment 3 comprising prebiotic
Bacterium fermentation step;Embodiment 11 is differed only in embodiment 3 comprising probiotics fermention step;Embodiment 12 and embodiment 3
Differ only in comprising probiotics fermention step.
Probiotics fermention step:Purified water is added into content obtained to be diluted, and is stirred evenly, it will be diluted interior
Tolerant be transferred in high-temperature sterilization pot is cured, is sterilized, and after the completion of sterilizing, content is transferred under aseptic condition naturally cold
But to room temperature.Cooling content is inoculated with probiotics and carries out hypoxemia fermentation, at interval of certain time in hypoxemia fermentation process
It is primary to stir content feed liquid.Hypoxemia is less than 25% after fermentation, by Rotary Evaporators concentrated broth to water content, system
The content that must be fermented.Wherein, the weight ratio (material-water ratio) of content and purified water, the sterilising temp of high-temperature sterilization pot, sterilizing
Time, the inoculum concentration of probiotics, the temperature of hypoxemia fermentation, the time of hypoxemia fermentation, stirring interval time and oxyty
Referring to table 2.
Table 2
| Embodiment 7 | Embodiment 8 | Embodiment 9 | Embodiment 10 | Embodiment 11 | Embodiment 12 | |
| Material-water ratio | 1:1 | 1:4 | 1:3 | 1:3 | 1:2 | 1:5 |
| Sterilising temp (DEG C) | 121 | 105 | 115 | 110 | 115 | 120 |
| Sterilization time (h) | 5 | 15 | 10 | 8 | 8 | 5 |
| Lactobacillus rhamnosus (g) | 1 | 0.2 | 0.25 | \ | 0.4 | 0.5 |
| Lactobacillus plantarum (g) | 1 | 1 | 1 | 0.5 | 1.5 | \ |
| Aspergillus oryzae (g) | 1 | 2 | 2 | 2 | 4 | 2.5 |
| Bacillus bulgaricus (g) | 1 | 0.2 | 0.25 | 0.5 | 0.4 | 0.25 |
| Bifidobacterium longum (g) | 1 | 1 | 1 | 1 | 2 | 0.25 |
| Fermentation temperature (DEG C) | 40 | 37 | 38 | 39 | 35 | 36 |
| Fermentation time (d) | 10 | 6 | 7 | 8 | 9 | 5 |
| Stir interval time (h) | 6 | 7 | 8 | 9 | 10 | 12 |
| Oxyty (%) | 6 | 7 | 8 | 8 | 9 | 10 |
In above-mentioned table 2, mix bacterium agent is at least one of Lactobacillus rhamnosus agent and lactobacillus plantarum agent and aspergillus oryzae
Microbial inoculum, bacillus bulgaricus agent and the compound probiotic agent of bifidobacterium longum agent composition.Wherein, sandlwood in Lactobacillus rhamnosus agent
The quantity of aspergillus oryzae, Bao Jiali in the quantity of lactobacillus plantarum, aspergillus oryzae microbial inoculum in the quantity of sugared lactobacillus, lactobacillus plantarum agent
The quantity of bifidobacterium longum is 4 × 10 in the quantity of bacillus bulgaricus, bifidobacterium longum agent in sub- bacillus agent6A/g.
Comparative example 1
Drug in comparative example 1 for treating chronic urticaria is commercially available loratadine tablet.
The recruitment evaluation of notoginseng-red sage capsule
Chronic urticaria patients data:Chronic urticaria patients 130 will be diagnosed as and be used as research object, met"Skin
Skin venereology"In the diagnostic criteria in relation to chronic urticaria.The age distribution of 130 patients is 17~49 (35.2 ± 8.1),
In, male patient 81, female patient 49 presses the time sequencing number 1-130 of income outpatient service.Experimental group A includes 1-10
Number 10 patients;Experimental group B includes No. 11-20 10 patients;And so on, control group includes No. 121-130 10 patients.13
Age, gender and not statistically significant (the P (s > of course of disease comparing difference of group chronic urticaria patients;0.05) it, is comparable.
Therapy:The chronic urticaria patients of the experimental group A Radix Notoginseng that daily morning and evening prepared by each primary oral embodiment 1 is red
The chronic urticaria patients notoginseng-red sage capsule that daily morning and evening prepared by each primary oral embodiment 2 of ginseng capsule one, experimental group B
One, the chronic urticaria patients of the experimental group C notoginseng-red sage capsule one that daily morning and evening prepared by each primary oral embodiment 3,
The chronic urticaria patients of the experimental group D notoginseng-red sage capsule one that daily morning and evening prepared by each primary oral embodiment 4, with such
It pushes away, the chronic urticaria patients notoginseng-red sage capsule one that daily morning and evening prepared by each primary oral embodiment 12 of experimental group L is right
According to the chronic urticaria patients loratadine tablet in each oral contrast embodiment 1 daily morning and evening of group, oral dose is every
Secondary 1, every contains 5mg Loratadine active ingredients.130 patients receive the treatment phase in January.
(1) wheal quantity and itch scale evaluation
Wheal quantity counting criteria:Patient's body after wheal quantity and receiving treatment 2h before statistics treatment on patient body
Wherein, one big wheal is equal to 3 small wheals to wheal quantity on body, and is ultimately converted to small wheal and is counted.Count knot
Fruit is referring to table 3.
Table 3
Note:It is pretherapy and post-treatment that * indicates that each experimental group receives, difference extremely significantly (p<0.01);# indicates experimental group and control group
It compares, significant difference (p<0.05);## is indicated except experimental group is compared with the control group compared with difference extremely significantly (p<0.01).
As seen from the results in Table 3, the notoginseng-red sage capsule that prepared by embodiment 1-12 can have as commercially available loratadine tablet
Effect reduces the wheal quantity with chronic urticaria patients, the extremely significantly (P< of the wheal quantity variance before and after treatment patients;
0.01).Compared with the commercially available loratadine tablet of control group, notoginseng-red sage capsule prepared by embodiment 7-12 has and preferably reduces
The effect of wheal quantity has the effect of preferably treating chronic urticaria.Wherein, the notoginseng-red sage that prepared by embodiment 8-10
For capsule compared to the commercially available loratadine tablet of control group, wheal quantity declines extremely significantly (P<0.01), embodiment 7, embodiment 11 with
And notoginseng-red sage capsule prepared by embodiment 12, compared to the commercially available loratadine tablet of control group, wheal quantity declines significantly (P<
0.05)。
The itch degree score after the score of itch degree and receiving treatment 2h before statistics treatment on patient body.Together
When, receive to treat January, statistics cures Chronic nettle rash Patients on Recurrence situation, that is, the case of chronic urticaria recurrence occurs
Number.Itch degree score standard:0 point, no gargalesthesia;1 point, slight gargalesthesia does not influence work, studying and living;2 points, severe gargalesthesia
But it can endure, influence normal study, work, life and sleep to a certain degree;3 points, severe gargalesthesia can not be endured, and seriously affect just
Often study, work, life and sleep.Statistical result is shown in Table 4.
Table 4
Note:* indicate that each experimental group receives before and after treatment, significant difference (p<0.05);* indicates that each experimental group receives treatment
It is front and back, difference extremely significantly (p<0.01);# indicates experimental group compared with the control group compared with significant difference (p<0.05).
By 4 result of above-mentioned table it is found that experimental group A-L and control group receive after treating, itch degree is declined,
In, identical as control group, after experimental group B, experimental group C, experimental group G-L receive treatment, the itch degree decline of patient is extremely notable
(p<0.01), show that notoginseng-red sage capsule prepared by embodiment 2, embodiment 3, embodiment 7-12 has treatment chronic urticaria
There is highly significant effect.It is compared with control group (commercially available loratadine tablet), after the treatment patients of experimental group G-L,
Patient's itch degree is generally less than control group, and the itch degree after wherein experimental group I treatments declines significantly (p< compared to control group;
0.05), there is statistical significance.After statistics treats January, the recurrence of Chronic nettle rash is cured, the results showed that control
There is higher chronic urticaria recurrence rate in group, and nettle rash recurrence seldom occurs in experimental group A-L.Show embodiment 1-12
The Traditional-Chinese-medicine-type notoginseng-red sage capsule of preparation is used to treat chronic urticaria compared to the chlorine for being commercially for treatment chronic urticaria
His stator of thunder is lower with preferably therapeutic effect, recurrence rate.
Improve the assessment of fatigue and sleep state
Random storage 150 is diagnosed as the patient of chronic urticaria, is randomly divided into three groups:Loratadine control group does not ferment
Capsules group and fermentation Capsules group.It counts 150 chronic urticaria patients and is receiving pretherapy and post-treatment fatiguability degree, sleep shape
Condition.Therapy:The patient for Capsules group of the not fermenting notoginseng-red sage capsule one that daily morning and evening prepared by each primary oral embodiment 3
Patient notoginseng-red sage capsule one, the Loratadine pair that daily morning and evening prepared by each primary oral embodiment 9 of grain, fermentation Capsules group
It is each primary oral containing commercially available loratadine tablet one daily morning and evening according to the patient of group, continue two months.Specific fatiguability degree is commented
The method of estimating is:It is both required to continuously read novel 1h before and after 150 treatment patients, the fatigue of patient is consulted after reading
Situation.Degree of fatigue includes:Very tired, feeling of fatigue significantly, slightly fatigue, energetic four grades.Statistical result is shown in Table
5.Specifically sleep state appraisal procedure is:Night, which wakes up 5 times or more (i.e. intermittent sleep) or is difficult to the person of falling asleep, to be calculated as sleeping
Difference, night wake up 3-4 time be calculated as sleeping poor, night wake up 1-2 time be calculated as sleeping generally, night sufficient uninterrupted sleep is calculated as sleeping
It is excellent, totally four grades.Statistical result is shown in Table 6.
Table 5
As shown in table 5, compared to Loratadine control group, prepared by the notoginseng-red sage capsule and embodiment 9 of the preparation of embodiment 3
Notoginseng-red sage capsule can significantly improve the fatiguability situations of chronic urticaria patients, wherein by after probiotics fermention
Notoginseng-red sage capsule have the effect of preferably improving fatiguability situation.
Table 6
As shown in table 6, compared to Loratadine control group, prepared by the notoginseng-red sage capsule and embodiment 9 of the preparation of embodiment 3
Notoginseng-red sage capsule can significantly improve the sleep states of chronic urticaria patients, wherein by after probiotics fermention
Notoginseng-red sage capsule has the effect of preferably improving sleep state, and the sleep quality of patient is obviously improved.
In conclusion the notoginseng-red sage capsule for including the preparation of probiotics fermention step is curing chronic urticaria, reduction
Chronic urticaria recurrence, improvement sleep, improvement fatiguability situation etc. show more preferably effect, this may be with benefit
It is related that raw bacterium fermentation process produces multiple beneficial metabolin, for example, multivitamin (including vitamin D, vitamin K), big point
Sub- polysaccharide, amino acid, unsaturated fatty acid etc..On the one hand these beneficial metabolites and beneficial flora can improve the intestines of body
Ecological microenvironment in road, balance body immune level improve sleep and improve fatiguability situation.
The above embodiment is only the preferred embodiment of the present invention, and the scope of protection of the present invention is not limited thereto,
The variation and replacement for any unsubstantiality that those skilled in the art is done on the basis of the present invention belong to institute of the present invention
Claimed range.
Claims (10)
1. a kind of notoginseng-red sage capsule, which is characterized in that including content and capsule shells, by weight, the content packet
Include 150~300 parts of Radix Notoginseng powder, 150~250 parts of Salvia root P.E, 10~50 parts of yeast beta-dextran, silica 1~10 part
And 0.5~2.5 part of magnesium stearate.
2. notoginseng-red sage capsule as described in claim 1, which is characterized in that the Radix Notoginseng powder is 200~250 parts, the pellet
Conopsea extraction is 170~210 parts, and the yeast beta-dextran is 25~40 parts, and the silica is 2~5 parts, the tristearin
Sour magnesium is 1~2 part.
3. notoginseng-red sage capsule as claimed in claim 2, which is characterized in that the Radix Notoginseng powder is 225 parts, the Radix Salviae Miltiorrhizae extraction
Object is 186.67 parts, and the yeast beta-dextran is 33.33 parts, and the silica is 3.6 parts, and the magnesium stearate is 1.4
Part.
4. notoginseng-red sage capsule as described in claim 1, which is characterized in that the fineness of the Radix Notoginseng powder is higher than 100 mesh, described
Radix Notoginseng powder is used to prepare notoginseng-red sage capsule after radiation sterilizing.
5. notoginseng-red sage capsule as described in claim 1, which is characterized in that the ethyl alcohol that the Salvia root P.E is 50~75%
Extract concentrate made from Radix Salviae Miltiorrhizae.
6. such as the preparation method of Claims 1 to 5 any one of them notoginseng-red sage capsule, which is characterized in that including following step
Suddenly:
Prepare content:Radix Notoginseng powder, Salvia root P.E, yeast beta-dextran, silica and stearic acid are weighed according to proportioning
Magnesium is uniformly mixed and crosses 80 mesh sieve;
Compression moulding:Capsule shells feed liquid and content material liquid compression moulding are taken, 0.45g/ notoginseng-red sage capsules are made.
7. the preparation method of notoginseng-red sage capsule as claimed in claim 6, which is characterized in that further include probiotics fermention step
Suddenly, purified water dilution is added into content obtained, and diluted content is transferred to curing at 105~121 DEG C, sterilizing 5
~15min, cooled to room temperature, hypoxemia ferments 5~10 days under the conditions of being inoculated with 1~10 part, 35~40 DEG C of probiotics, hypoxemia
After fermentation, concentrated broth is for use;
Wherein, the weight ratio of content feed liquid and purified water is 1:1~5, it is stirred at interval of 6~12h in hypoxemia fermentation process
Content feed liquid is primary, and the oxyty in the hypoxemia fermentation is 6~10%;
And the probiotics are at least one of Lactobacillus rhamnosus and lactobacillus plantarum and bacillus bulgaricus, length
The mix bacterium agent of Bifidobacterium and aspergillus oryzae composition.
8. the preparation method of notoginseng-red sage capsule as claimed in claim 7, which is characterized in that the probiotics are rhamnose
The mix bacterium agent of lactobacillus, lactobacillus plantarum, bacillus bulgaricus, bifidobacterium longum and aspergillus oryzae composition, the probiotics
It is 3~10 parts;
Wherein, the ratio of number of Lactobacillus rhamnosus, lactobacillus plantarum, bacillus bulgaricus, bifidobacterium longum and aspergillus oryzae
It is 1:1~5:1:1~5:10.
9. the preparation method of notoginseng-red sage capsule as claimed in claim 7, which is characterized in that the probiotics are 4.5 parts,
Hypoxemia ferments 7 days under the conditions of 38 DEG C;
The zymotic fluid is concentrated into water content and is less than 25%.
10. the preparation method of notoginseng-red sage capsule as claimed in claim 7, which is characterized in that in the probiotics, sandlwood
The quantity of sugared lactobacillus is 1 × 106A, the quantity of lactobacillus plantarum is 4 × 106A, the quantity of bacillus bulgaricus is 1 × 106
A, the quantity of bifidobacterium longum is 4 × 106A, the quantity of aspergillus oryzae is 8 × 106It is a.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810802196.4A CN108685981A (en) | 2018-07-20 | 2018-07-20 | A kind of notoginseng-red sage capsule and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810802196.4A CN108685981A (en) | 2018-07-20 | 2018-07-20 | A kind of notoginseng-red sage capsule and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108685981A true CN108685981A (en) | 2018-10-23 |
Family
ID=63851736
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810802196.4A Pending CN108685981A (en) | 2018-07-20 | 2018-07-20 | A kind of notoginseng-red sage capsule and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108685981A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114788845A (en) * | 2021-01-26 | 2022-07-26 | 四川福生源科技有限公司 | Traditional Chinese medicine composition with sleep improving effect and preparation method and application thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101394860A (en) * | 2006-01-13 | 2009-03-25 | 范斯坦医药研究院 | Inhibition of inflammatory cytokine production with tanshinones |
| CN107684583A (en) * | 2017-09-27 | 2018-02-13 | 徐运贞 | Treatment by Chinese herbs chronic urticaria and preparation method |
-
2018
- 2018-07-20 CN CN201810802196.4A patent/CN108685981A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101394860A (en) * | 2006-01-13 | 2009-03-25 | 范斯坦医药研究院 | Inhibition of inflammatory cytokine production with tanshinones |
| CN107684583A (en) * | 2017-09-27 | 2018-02-13 | 徐运贞 | Treatment by Chinese herbs chronic urticaria and preparation method |
Non-Patent Citations (3)
| Title |
|---|
| 朱娅敏，等: "酵母β-葡聚糖对小鼠免疫力增强作用的研究", 《食品与发酵科技》 * |
| 李振光: "荨麻疹", 《广西中医药》 * |
| 王永茂，等: "丹参酮的临床应用进展", 《邯郸医学高等专科学校学报》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114788845A (en) * | 2021-01-26 | 2022-07-26 | 四川福生源科技有限公司 | Traditional Chinese medicine composition with sleep improving effect and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6435333B2 (en) | Composition for prevention and treatment of cancer-related fatigue comprising processed ginseng powder or processed ginseng extract with increased ginsenoside component | |
| CN115120683B (en) | Raw material composition, traditional Chinese medicine fermented product, and preparation method and application thereof | |
| CN111840363B (en) | Natto-assisted hypoglycemic health-care composition and preparation method and application thereof | |
| CN112569323A (en) | Composition for dispelling effects of alcohol and protecting liver and application thereof | |
| CN113017092B (en) | Fermentation type small molecule peptide mixed solution for regulating blood sugar and preparation method and application thereof | |
| JP6626035B2 (en) | Pharmaceutical composition for prevention or treatment of sarcopenia and health food composition for prevention or improvement | |
| CN102266487B (en) | Kudzuvine root-containing composition for treating hyperlipemia and preparation method and application thereof | |
| CN107468999A (en) | A kind of fermentation composition with beauty treatment and eliminating spot function and preparation method thereof | |
| CN108685981A (en) | A kind of notoginseng-red sage capsule and preparation method thereof | |
| CN112021568A (en) | Medicinal and edible functional composition for assisting epidemic prevention of new coronavirus | |
| CN110251591A (en) | A kind of pharmaceutical composition and its preparation method and application that aided blood pressure-lowering is hypoglycemic | |
| KR102151373B1 (en) | Food Composition for Preventing and Improving Allergy Comprising Fermented Noni and Method for Preparing the Same | |
| CN108837001A (en) | A kind of notoginseng-red sage tablet and preparation method thereof | |
| CN113144167A (en) | Fermented small-molecule peptide mixed solution with uric acid reducing effect and preparation method and application thereof | |
| CN101167763B (en) | Monascus and total ginkgolide composition for preventing and treating cardiovascular and cerebrovascular diseases | |
| CN115088834B (en) | Sophora flower bud powder for improving sleep and preparation method and application thereof | |
| CN113332314B (en) | Oyster shell meat zymolyte and application thereof in preparation of medicines for treating depression | |
| CN105055856B (en) | A kind of Tea Pigment Chinese medicine composition and its preparation method and application for treating cardiovascular and cerebrovascular disease | |
| CN102631487B (en) | Traditional Chinese medicine composition capable of improving immunity and resisting fatigue | |
| TWI440465B (en) | Herbal extract mixture for reducing blood lipid and a combination thereof | |
| CN113456704B (en) | Pharmaceutical composition with gastrointestinal improving effect and preparation method and application thereof | |
| CN102631506B (en) | Traditional Chinese medicine composition capable of improving immunity and resisting fatigue | |
| CN102631486B (en) | Health care composition | |
| CN102657333B (en) | Blood pressure reducing and heart protecting composite nutrient and preparation method thereof | |
| KR20100129040A (en) | Method for producing functional health food containing bezoar bovis used microbes and the functional health food produced by the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20181023 |
|
| RJ01 | Rejection of invention patent application after publication |